Green et al. Application No.: 09/506,430 Page 2 Attorney Docket No.: 015542-002330US Client Reference No.: 121

CONCLUSION ----

In view of the remarks in this response and the previous response to the Restriction Requirement, Applicants request that the Restriction Requirement be withdrawn and early examination of all the claims on the merits conducted forthwith. Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,

Eric J. Baude

Reg. No. P-47,413

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834

Tel: (415) 576-0200 Fax: (415) 576-0300

EJB `

SF 1199891 v1

Green et al. Application No.: 09/506,430 Page 3

1

2

3

4

5 6

7

8

9

10

11

1

2

1

2

3

1

2

1

2

3

4

1

1

2

PATENT Attorney Docket No.: 15542-002330US Client Reference No.: 121

..... APPENDIX _____

18. (New) A method of inhibiting neovascularization in a subject in need thereof comprising:

administering to said subject a pharmaceutical preparation comprising a pharmaceutically acceptable carrier and an amount of a compound effective to inhibit neovascularization with the formula of R'-Glu-Trp-R" or pharmaceutically acceptable salts thereof,

wherein R' and R" is absent or a moiety independently selected from the group consisting of an amide, an imide, an ester, an anhydride, an ether, a methyl-alkyl ester, an ethyl-alkyl ester, an alkyl group, and an aryl group,

wherein R' is present if R" is absent and R" is present if R' is absent, wherein the formula weight of said compound is less than about 5000 Daltons.

- 19. (New) The method of claim 18, wherein the formula weight of said compound is less than about 1000 Daltons.
- 20. (New) The method of claim 18, wherein said compound is selected from the group consisting of:

Ac-Glu-Trp, Suc-Glu-Trp, Cpr-Glu-Trp, But-Glu-Trp, and pyroGlu-Trp.

- 21. (New) The method of claim 18, wherein said pharmaceutically acceptable salt is selected from the group consisting of sodium, potassium, ammonium, zinc, magnesium, and calcium.
- 22. (New) The method of claim 18, wherein said pharmaceutically acceptable salt is selected from the group consisting of hydrochloride, hydrobromide, sulfate, bisulfate, acetate, oxalate, valarate, oleate, laurate, benzoate, lactate, phosphate, tosulate, citrate, maleate, fumarate, succinate, and tartrate.
 - 23. (New) The method of claim 18, wherein the condition is hemangioma.
- 24. (New) The method of claim 18, wherein the condition is vascularized malignant tumor or vascularized benign tumor.

Green et al. Attorney Docket No.: 15542-0023301 Application No.: 09/506,430 Client Reference No.: 121 Page 4 (New) The method of claim 24, wherein the tumor is a tumor of the 25. meninges, an intracerebral tumor, a sarcoma, an osteosarcoma, a tumor of the esophagus, or a tumor of the trachea. (New) The method of claim 24, wherein the tumor is a Lewis 26. carcinoma. (New) The method of claim 24, wherein the tumor is Kaposi's 27. sarcoma. (New) The method of claim 18, comprising administering to the 28. subject a dose of said compound of about $0.5~\mu g$ per 1 kilogram body weight to about 1~mgper 1 kg body weight. (New) The method of claim 28, wherein the effective amount is about 29. 1 μg/kg to about 50 μg/kg body weight. (New) The method of claim 28, wherein said dose is administered 30. daily over a period of 1 day to about 30 days. (New) The method of claim 18, wherein said pharmaceutical 31. preparation is administered intramuscularly, intranasally, transdermally, or intrabronchially. (New) The method of claim 18, wherein said pharmaceutical 32. preparation is administered intravenously, intraperitoneally, subcutaneously, or gastrointestinally. (New) The method of claim 18, wherein said pharmaceutical 33. preparation is an injectable solution comprising 0.001% to 0.01% of said compound. (New) The method of claim 18, wherein said pharmaceutical 34. preparation is in a unit dose form comprising a tablet, a suppository, a capsule, an eye film, an inhalant, a mucosal spray, a nose drop, an eye drop, a toothpaste, an ointment, a watersoluble based cream, a solution, or a saline solution.

1

·2 3

> 1 2

1 2

1

2

1

2

1

2

1

2

1

2

3

1

2

1

2

3

4

1

2

1

2

1

2

1

2

1

2

1

2

3

1

2

3

4

1

2